收费全文 | 344648篇 |
免费 | 17871篇 |
国内免费 | 865篇 |
耳鼻咽喉 | 4344篇 |
儿科学 | 10381篇 |
妇产科学 | 7316篇 |
基础医学 | 48499篇 |
口腔科学 | 8327篇 |
临床医学 | 27807篇 |
内科学 | 77251篇 |
皮肤病学 | 9565篇 |
神经病学 | 31879篇 |
特种医学 | 10955篇 |
外国民族医学 | 129篇 |
外科学 | 45381篇 |
综合类 | 1650篇 |
一般理论 | 89篇 |
预防医学 | 29349篇 |
眼科学 | 6308篇 |
药学 | 23430篇 |
中国医学 | 1017篇 |
肿瘤学 | 19707篇 |
2023年 | 1897篇 |
2022年 | 2324篇 |
2021年 | 6841篇 |
2020年 | 3882篇 |
2019年 | 6876篇 |
2018年 | 10431篇 |
2017年 | 7009篇 |
2016年 | 7266篇 |
2015年 | 8108篇 |
2014年 | 9750篇 |
2013年 | 14392篇 |
2012年 | 23358篇 |
2011年 | 23568篇 |
2010年 | 12552篇 |
2009年 | 10488篇 |
2008年 | 19940篇 |
2007年 | 21090篇 |
2006年 | 19642篇 |
2005年 | 19603篇 |
2004年 | 18058篇 |
2003年 | 16773篇 |
2002年 | 15820篇 |
2001年 | 8675篇 |
2000年 | 8662篇 |
1999年 | 7704篇 |
1998年 | 2169篇 |
1997年 | 1703篇 |
1996年 | 1513篇 |
1995年 | 1338篇 |
1994年 | 1150篇 |
1992年 | 4131篇 |
1991年 | 3765篇 |
1990年 | 3530篇 |
1989年 | 3145篇 |
1988年 | 2951篇 |
1987年 | 2771篇 |
1986年 | 2644篇 |
1985年 | 2421篇 |
1984年 | 1841篇 |
1983年 | 1549篇 |
1979年 | 1553篇 |
1978年 | 1102篇 |
1975年 | 1086篇 |
1974年 | 1282篇 |
1973年 | 1276篇 |
1972年 | 1199篇 |
1971年 | 1176篇 |
1970年 | 1121篇 |
1969年 | 1160篇 |
1968年 | 1018篇 |
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
Area covered: The current review is provided to update recent developments in the clinical application of cyclin/CDK inhibitors to breast cancer with a focus on the anti-tumor immune response.
Expert opinion: The cyclin D1 gene encodes the regulatory subunit of a proline-directed serine-threonine kinase that phosphorylates several substrates. CDKs possess phosphorylation site selectivity, with the phosphate-acceptor residue preceding a proline. Several important proteins are substrates including all three retinoblastoma proteins, NRF1, GCN5, and FOXM1. Over 280 cyclin D3/CDK6 substrates have b\een identified. Given the diversity of substrates for cyclin/CDKs, and the altered thresholds for substrate phosphorylation that occurs during the cell cycle, it is exciting that small molecular inhibitors targeting cyclin D/CDK activity have encouraging results in specific tumors. 相似文献
Areas covered: This review includes a view of the clinical classification and risk assessment in children suffering from HL. The chemotherapy more commonly employed is revisited. The use of PET/CT to evaluate the disease in order to guide therapy is analyzed. New options of chemotherapy and emerging immunotherapy are also included.
Expert opinion: In order to make the right treatment choice, a proper initial assessment of risk is mandatory. The choice of therapy in these kinds of patients must be done according to the experience of the team, and also, the cost and logistics related to the eligible scheme are very important. If possible, efforts must be made to include PET/CT in guiding therapy and avoiding overtreatment and long-term adverse effects in children. New options in immunotherapy are emerging and must be considered with caution in selected patients. 相似文献